A synthetic analog of the immune peptide tuftsin, registered as an anxiolytic in Russia and studied for anxiety, with mostly small trials and preclinical data.
Reviewed for accuracy · Last reviewed July 7, 2026Selank is a synthetic heptapeptide derived from tuftsin, an endogenous immunomodulatory peptide, with an added stabilizing tail. It was developed in Russia and has been registered there since 2009 as an anxiolytic for generalized anxiety disorder and neurasthenia. It has no FDA or EMA approval and is treated as a research compound in the West. Like Semax, it is typically given intranasally.
Its proposed anti-anxiety mechanism involves the GABA system, though cell studies suggest it modulates GABA signaling indirectly rather than acting as a direct agonist. The main human evidence is a small Russian comparative trial in which Selank performed broadly comparably to the benzodiazepine medazepam. Everything else is preclinical, so its effects should be read as preliminary rather than well established.
Selank is dosed intranasally by the specific Russian product where it is registered, so there is no single Western dosing guideline. Community figures are extrapolation rather than validated regimens.
Read the full Selank dosage guide →Human safety data is limited to small Russian studies. As an intranasal peptide the effect most often mentioned is mild nasal irritation, and its broader adverse-effect profile is not well characterized.
Read the full Selank side effects guide →Keep the unmixed peptide refrigerated and away from light, and store any reconstituted intranasal solution refrigerated. See the full storage & safety guide for handling and disposal basics.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.